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Background: Almost all assisted reproductive technology (ART) and intrauterine insemination (IUI) treatments
performed in Australia are subsidized through the Australian Government’s universal insurance scheme, Medicare. In
2010 restrictions on the amount Medicare paid in benefits for these treatments were introduced, increasing patient
out-of-pocket payments for fresh and frozen embryo ART cycles and IUI. The aim of this study was to evaluate the
impact of the policy on access to treatment, savings in Medicare benefits and the number of ART conceived
children not born.
Methods: Pooled quarterly cross-sectional Medicare data from 2007 and 2011 where used to construct a series of
Ordinary Least Squares (OLS) regression models to evaluate the impact of the policy on access to treatment by
women of different ages. Government savings in the 12 months after the policy was calculated as the difference
between the predicted and observed Medicare benefits paid.
Results: After controlling for underlying time trends and unobserved factors the policy change reduced the
number of fresh embryo cycles by almost 8600 cycles over 12 months (a 16% reduction in cycles, p< 0.001). The
policy effect was greatest on women aged 40 years and older (38% reduction in cycles, p< 0.001). Younger women
engaged in relatively more anticipatory behaviour by bringing forward their fresh cycles to 2009. Frozen embryo
cycles, which are approximately one quarter of the cost of a fresh cycle, were only marginally impacted by the
policy. Utilisation of IUI cycles were not impacted by the policy. After adjusting for anticipatory behaviour, $76
million in Medicare benefits was saved in the 12 months after the policy change (0.47% of annual Medicare
benefits). Between 1200 and 1500 ART conceived children were not born in 2010 as a consequence of the policy.
Conclusions: The introduction of the policy resulted in a significant reduction in fresh ART cycles in the first
15 months after its introduction. Further evaluation on the long term impact of the policy with regard access to
treatment and on clinical practice, particularly the number of embryos transferred, is crucial to ensuring equitable
access to fertility treatment and the health and welfare of ART children.
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Infertility and its treatment
Infertility affects approximately 10% of couples at any given
time worldwide, representing significant personal suffering
to millions of couples around the globe. Based on recent
estimates, over 72 million women worldwide are currently* Correspondence: g.chambers@unsw.edu.au
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reproduction in any medium, provided the orinfertile, of which approximately 40 million will seek
healthcare assistance [1]. Fertility treatments range from
advice about how to optimise natural conception to com-
plex and invasive medical interventions including surgery
and assisted reproductive technologies (ART). ARTs are
generally considered to include all treatments or proce-
dures that include the in vitro handling of human oocytes
[eggs] and sperm or embryos for the purposes of establish-
ing a pregnancy [2]. The most common ART is in vitro fer-
tilisation (IVF). A typically ART ‘cycle’ involves the
stimulation of a woman’s ovaries with hormones totral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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under anaesthesia, fertilisation of the eggs outside of the
body to create embryos, and the transfer of one or more 2-
6 day-old embryos back into the woman’s uterus. This type
of ART cycle is termed a fresh embryo transfer cycle (Fresh
Cycle). Excess embryos can be frozen and transferred back
into the woman at a later date in what is termed a frozen
embryo transfer cycle (Frozen Cycle). Around 20% of ART
cycles result the birth of a live born child. However, the
type of cycle (e.g. Fresh or Frozen), female age, number of
previous treatment attempts and type of infertility all con-
tribute to the likelihood of success [3-5]. Since the birth of
the first ART baby - Louise Brown in England in 1978 -
over 4.7 million babies have been born worldwide from
ART treatments. The use of ART treatment is increasing
by 5-10% per annum in most countries with the worldwide
activity estimated to be 1.5 million cycles per year [6].
While access and demand for ART treatment varies signifi-
cantly between countries - especially between developed
and developing countries - up to 5% of children in some
countries are now conceived through ART treatments [3].
ARTs are the most advanced fertility treatments available
and because of high medical, scientific, pharmaceutical and
staff costs are also the most expensive, with the cost of a
Fresh Cycle ranging from $12,500 US dollars (USD) in the
US to $4000 USD in Japan. Because a Frozen Cycle only
requires the transfer of a previously created embryo into a
women’s uterus, costs are generally one quarter of a Fresh
Cycle [7]. Multiple Fresh and Frozen Cycles may be needed
to achieve a pregnancy and many couples will discontinue
treatment after multiple failed attempts because of the fi-
nancial, emotional or physical burden of treatment. Along
with ARTs the most common form of medical intervention
to treat infertility is intrauterine inseminaton (IUI),
whereby sperm - a partner’s or donor’s - is deposited dir-
ectly into a woman’s uterus to aid conception. This can be
either performed in a treatment cycle where the ovaries
have been stimulated with hormones to mature multiple
eggs or in an unstimulated cycle.
Funding arrangement for fertility treatment
Funding arrangements for ART and IUI vary substan-
tially across jurisdictions, countries and time, ranging
from almost unrestricted funding in Israel to no public
funding in the US, South America and most developing
countries. [7,8]. Australia has had a tradition of support-
ive public funding of ART and IUI treatment through its
universal healthcare insurance system, Medicare. Since
2000, women have been eligible for partial reimburse-
ment of all ‘medically necessary’ ART and IUI cycles re-
gardless of age or numbers of previous cycles and
children. The most significant policy change to affect
funding of ART in the last decade was the introduction
of the Extended Medicare Safety Net (EMSN) in 2004.This policy is applicable to all out-patient Medicare ser-
vices and was introduced to assist patients with high
out-of-pocket expenses. The EMSN reimburses 80% of
future out-of-pocket expenses for all out-patient Medi-
care services once an annual threshold is reached. This
scheme had a significant impact of ART and IUI treat-
ments because they are high cost treatments mostly
undertaken in an out-patient setting. With the average
cost of a Fresh Cycle in Australia being about $8000,
Australian dollars (AUD) most patients reached their
out-of-pocket threshold after just one treatment cycle,
making additional ART or IUI cycles in the calendar
qualify for EMSN benefits. The EMSN policy effectively
reduced patient out-of-pocket expenses for a Fresh Cycle
from approximately $4000 to $1500. Primarily because
of this, utilisation of ART treatments increased by 72%
over five years from 31,200 cycles in 2003 to 53,600
cycles in 2008. The benefits paid by Medicare increased
by over 300% from $50.0 M to $202.2 M over the same
period because of the increase in utilisation and the in-
crease in benefits paid per cycle under the EMSN
scheme (Figure 1).
A review of the EMSN scheme in 2006, found that
ART treatment comprised 22% of all benefits paid by
the EMSN scheme. It concluded that due to the unlim-
ited nature of the benefits available through the EMSN
scheme some of the 68 private fertility clinics in Australia
opportunistically raised their fees in the knowledge that
the majority of the cost would be funded by govern-
ment - this meant that patients did not fully see the re-
duction in out-of-pocket expenses that the EMSN
scheme had been designed to support [9]. In response to
these findings, ‘caps’ on the amount of EMSN benefits that
could be paid for ART and IUI treatment were announced
in October 2009 and implemented in January 2010. In
effect this meant that if the fees charged by fertility
clinics remained unchanged, patient would need to pay
more for their treatment while the government would
pay less. Out-of-pocket expenses increased for Fresh
Cycles by $500-$1000 to ~ $2000-$2500 per cycle, for
Frozen Cycles by $300-$500 to ~ $1000 per cycle and
for IUI Cycles by $300-$500 to ~ $600 per cycle. The
changes to the EMSN scheme in relation to fertility
treatment was expected to provide savings of $69.4 mil-
lion annually [10].
The aims of this study are to evaluate the impact of
the EMSN ‘caps’ (hereon referred to as EMSNCaps) on:
i. Access ART treatment (Fresh and Frozen Cycles)
and IUI Cycles by different age groups of women
seeking treatment.
ii. Savings achieved by the Australian Government in
Medicare benefits from the EMSNCap policy with
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Figure 1 ART treatment cycles and Medicare Benefits Scheme benefits, Australia 2011-2010. Source: Medicare online statistics: http://
www.medicareaustralia.gov.au/provider/medicare/mbs.jsp#N10030.
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infants not born in the first year after the EMSNCap




Pooled cross-sectional data on ART and IUI services
undertaken between January 2007 and June 2011 were
obtained from the Australian Government’s Medicare
Information Service Branch. The data were extracted
from a national dataset of all services for which Medi-
care benefits are paid (estimated to be 100% of Fresh
and Frozen Cycles performed in Australia). The data
included counts of persons and services, average pro-
vider fees and Medicare benefits. To evaluate the impact
of the EMSNCaps on ART and IUI access by female age
(<32, 32-33, 34-35, 36-37, 38-39, 40-41, 42 + years)
Medicare provided quarterly averages of the provider
fees charged, Medicare benefits paid and out-of-pocket
expenses for the different cycle types. Medicare Australia
supplied these data for nine ART Medicare Benefits
Schedule (MBS) items before the Caps and eleven MBS
items after the Caps; 13200 (fresh embryo ART cycle),
13201(subsequent fresh embryo ART cycle in a calendar
year, introduced in 2010), 13202 (cancelled ART treat-
ment before oocyte retrieval, introduced in 2010), 13203
(ovulation induction for IUI), 13209 (planning and man-
agement of ART or IUI), 13212 (oocyte retrieval), 13215
(fresh embryo transfer before 2010 and fresh or frozen
embryo transfer after 2010), 13218 (frozen embryo
transfer cycle), 13221 (semen preparation), 13251(intracytoplasmic sperm injection). A combination of
these MBS items are used to bill Medicare for ART and
IUI treatment and represent the type and sequential
steps in each type of treatment cycle. For example, an
initial Fresh Cycle performed in a calendar year after
2010 would typically incur Medicare MBS items 13209,
13200, 13201, 13215, 13218 (Table 1). The age-stratified
data represented 84 observations before the caps and 42
observations after the caps. However, because not all
claims had been lodged with Medicare at the time of the
data extraction, estimates pertaining to utilisation rates
for the second quarter of 2011 were excluded.
Because multiple MBS items represent an ART cycle,
the analysis was undertaken based on an ‘episode of care’
for undertaking a Fresh Cycle, Frozen Cycle or IUI Cycle.
The steps involved in preparing the MBS item-based data
to represent a treatment cycle involved the following
steps for each age group, time period and cycle type.
1. Dollar figures for provider fees and Medicare
benefits were converted to constant 2010 dollars
using the ABS Health Price Index [11].
2. Provider fees and Medicare benefits for each MBS
item were calculated as the total average fee and
benefits divided by the no of services.
3. Out-of-pocket expenses were calculated as the average
provider fee minus the average Medicare benefit.
4. The average cycle-based provider fees, benefits and
out-of-pocket expenses for each of the three cycle
types were calculated by summing weighted averages
for each of the MBS items associated with a Fresh,
Frozen and IUI cycle (Table 1).
Table 1 Medicare Benefits Schedule (MBS) Assisted Reproductive Technology (ART) billing items
Cycle type Before January 2010 After January 2010
(pre EMSNCap policy) (post EMSNCap policy)
Fresh Cycle (uniquely identified by items 13200 and 13201) 13209, 13200, 13212, 13215, 13221, 13251 13209, 13200, 13212, 13201, 13215, 13251
Frozen Cycle (uniquely identified by item 13218) 13209, 13218 13209,13215,13218
IUI Cycle (identified by item 13203) 13209, 13203, 13221 13209, 13203, 13221
Notes:
13209: This item is assigned to all ART treatment types. Before 2010 it was typical for providers to assign a much higher fee to Fresh Cycles than either Frozen
Cycles of IUI. Based on a survey of ART provider charging practices in 2007, the average fees, MBS benefits and OOPs were assigned to Frozen Cycles and IUI
Cycles were 34% of the weighted average fee of 13209 assigned to a Fresh cycle, by quarter and age group.
13251: This item is used to bill intracytoplasmic sperm injection which is a laboratory technique to aid fertilisation. The average fees, Medicare benefits, OOPs, and
number of ICSI services and patients were assigned to each quarter and age group based on the proportion of 13200 and 13201 cycles attracting a 13251 item.
13203: Prior to 2010, the MBS item 13203 was assigned to both cancelled Fresh Cycles and IUI cycles. After 2010, a specific MBS item was created for cancelled
Fresh Cycles (13202) and item 13203 was retained for IUI. Therefore to estimate utilisation for IUI cycles before the 2010, the age-specific proportion of 13202 to
13203 items performed in 2010 was used to adjust service and patient counts for MBS item 13203.
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identify utilisation of Fresh Cycles and MBS Item
13218 was used to uniquely identify Frozen Cycles.
MBS Item 13203 was used to identify IUI utilisation,
however an adjustment was made to account for
MBS Item 13203 also being used to bill cancelled
ART cycles before 2010.
Ethics approval for this project was obtained from The
University of New South Wales, Human Research Ethics
Committee.Empirical analysis
The effect of the EMSNCap policy on women in different
age categories
A series of Ordinary Least Squares (OLS) regression
models were used to evaluate whether the introduction
of EMSNCaps was associated with significant changes in
access to Fresh, Frozen and IUI Cycles by women of dif-
ferent ages. The quarterly pooled cross-sections of Medi-
care data stratified by age between January 2007 and
June 2011 were used to construct the following model.
yita ¼ β0 þ β1EMSNCap þ β2Timetrendt¼1;...;18
þ β3Seasonal dummyþ β4y1 þ 2ita ð1Þ
In essence the time-trend was compared for each of
the three cycle types before and after the EMSNCap was
introduced in 2010. The two dependent variables for
each cycle type were (i) number of cycles, and (ii) num-
ber of patients for cycle type i in quarter t and age a
(reported by age groups ≤33, 34-39 and ≥40 years). A
linear ordinal time-trend independent variable (Time-
trend) was included to capture underlying trends in the
data and quarterly seasonal dummies (Seasonal dummy)
were included to control for the highly seasonal nature
of the data. To capture the ceterus paribus impact of the
policy change, a step dummy variable (EMSNCap) was
used to impose a permanent shift in the level of theseries, taking the value of 0 before 2010 and 1 after
2010. The dependent variable was lagged by one time
period for each age group to take account of inertia inher-
ent in patients’ decisions to undertake fertility treatment,
existing capacity of fertility clinics, and age-specific unob-
served factors. The estimated coefficient of the lag of the
dependent variable was statistically significant for all mod-
els. Further, the R square statistic was greater for all age-
specific models with lag compared to those without indi-
cating better fitted estimates.Anticipatory behaviour
The introduction of the EMSNCap policy was
announced in October 2009, but not implemented until
January 2010. It was evident from the service counts that
patients brought forward their ART treatment to 2009
in anticipation of the policy change, in effect having
their treatment before the ‘price rise’. To account for
this anticipatory behaviour, the average percentage
change from the third quarter to the fourth quarter in
2007 and 2008 was used to adjust the service and patient
counts for each age group in the fourth quarter in 2009
and the first quarter in 2010. This adjustment reduced
the number of cycles undertaken in the fourth quarter in
2009 and increased them in the first quarter of 2010, in
effect removing the anticipatory behaviour from the
data. Results are reported with and without the adjust-
ment of anticipatory behaviour.Distribution of the number of cycles in each year
To determine if the number of cycles undertaken by an
individual women in a calendar year have changed in re-
sponse to the EMSNCap policy, data on the distribution
of patients undergoing 1, 2, 3, and ≥4 Fresh and Frozen
Cycles was obtained. A chi squared statistic was used to
test for differences in the annual proportion of cycles
undertaken by women before the EMSNCap (2007-2009)
with the first year after the EMSNCap (2010).
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performed due to policy
To estimate the savings to the Australian Government
in Medicare benefits and the number of cycles not
undertaken in the first year after EMSNCaps were
introduced (2010), we calculated the difference between
the predicted values of these two dependent variables
(assuming the EMSNCap policy had not been intro-
duced) from the observed values for the dependent
variables. To do this, we regressed the average Medi-
care benefits and number of cycles using the age-
stratified data before 2010 (84 observations from 2007
to 2009), and used the resulting coefficients to predict
the Medicare benefits and number of cycles for the per-
iods after 2010 (42 observations from quarter 1, 2010
to quarter 2, 2011). The estimates were obtained using
Equation (1) with and without adjustment for anticipa-
tory behaviour. When estimating the co-efficients for
Medicare benefits, the lag of the dependent variable
was omitted because the EMSNCaps had an instantan-
eous effect of the amount Medicare paid in benefits for
fertility treatment.
The savings in Medicare benefits to the Australian
Government in 2010 were due to both (i) fewer cycles
being undertaken after the EMSNCap policy and (ii) the
cycles that were undertaken attracting less Medicare
benefits. Therefore to calculate the total savings in
Medicare benefits, we summed the following values for
each cycle type where the EMSNCap was shown to sig-
nificantly affect access:
1. Cycles not undertaken in 2010; calculated by
multiplying the number of cycles forgone by the
average predicted Medicare benefits that would have
been paid had the EMSNCaps policy not been
introduced.
2. Cycles undertaken in 2010; calculated by multiplying
the observed number of cycles undertaken in 2010
by the difference in the predicted and observed
Medicare benefits per cycle.
The number of live-births (defined as the delivery of at
least one live-born infant of at least 20 weeks gestation)
that would have been born had the EMSNCap policy
not been introduced was calculated by multiplying the
number of cycles foregone by the live-birth in Australia
in 2009. Because the price of ART treatment is higher
after the EMSNCap, this may create a financial incentive
to transfer higher numbers of embryos during treatment.
Therefore to allow for a possible increase in the ART
multiple birth rate after the EMSNCap policy, the num-
ber of live born babies was calculated using the multiple
birth rate from 2007 (10.2%) which is 2 percentage
points higher than in 2009 [4].Results
Descriptive statistics
Age specific groups, provider fees, Medicare benefits and
out-of-pocket costs
Prior to the introduction of the EMSNCaps there was an
annual increase in Fresh Cycles of +12% and +17% in
2008 and 2009 respectively. However with the introduc-
tion of the EMSNCaps, the number of Fresh Cycles per-
formed in 2010 decreased by - 21% from 40,017 in 2009
to 31,504 in 2010. After adjusting for anticipatory behav-
iour the annual decrease in Fresh Cycles in 2010 was -
16% (32,339). Compared with Fresh Cycles, the annual
increase in Frozen Cycles before the EMSNCaps fol-
lowed by the decrease after the policy was less pro-
nounced. There was a 5% and 9% annual increase in
Frozen Cycles in 2008 (19,085) and 2009 (21095), fol-
lowed by a 1% increase in cycles in 2010 (21,276). IUI
Cycle utilisation remained relatively unchanged before
the EMSNCaps at approximately 11,000 cycles in 2008
and 2009, followed by a decrease of 5% in 2010 (Table 2
and Figure 2).
Econometric results
Access to fresh cycles by age
Equation (1) was estimated to describe the effect of the
EMSNCap policy on three clinically relevant age groups
(≤33 years, 34-37 years, ≥38 years) and all ages combined
(Table 3). The estimated results show that the coefficient
on EMSNCap policy was negative and statistically signifi-
cant at 1% across all age groups, except for age group ≤33
(10% significance). Overall, the number of Fresh Cycles
decreases by 307 cycles per quarter for all age groups in
the 15 months after the EMSNCap, a decrease of 8596
cycles over 12 months. Specifically, the number of services
decreases by 430 and 497 cycles per quarter in the 34-
39 years and ≥40 years, respectively (p< 0.001), and 305
cycles per quarter in women aged ≤33 years (p< 0.1). After
adjusting for anticipatory behaviour, the number of Fresh
Cycles decreased by 195 cycles per quarter across all age
groups (5460 Fresh Cycles over 12 months). Interestingly
the magnitude of the policy effect was less in the ≤33 years
(183 Fresh Cycles) and 34-39 years (276 Fresh Cycles) age
groups than for women aged ≥40 years (437 Fresh Cycles),
indicating the women in the younger age groups engaged
in relatively more anticipatory behaviour by bringing their
treatment forward to 2009. This may be a reflection of the
price pressures created by the EMSNCaps being greater
for the younger age groups.
Estimates of the semi-log of Equation (1) show that
after accounting for anticipatory behaviour, the EMSN-
Cap policy caused a 16% decrease in the Fresh Cycles
across all ages, 14% for women aged ≤34 years, 21% for
woman aged 34-39 years and 38% for women aged
≥40 years (Table 4).
Table 2 Summary statistics for fertility treatments, Medicare Australia data, 2007-2011
2007 Q1 to 2009 Q4 2010 Q1 to 2011Q2
Pre EMSNCap Post EMSNCap
Fresh Cycles Obs Mean SD Min Max Obs Mean SD Min Max
No of Patients 84 1166 265 781 2130 35 1117 237 750 1831
Number of Cycles 84 1249 278 810 2241 35 1137 237 751 1856
Average provider fees 84 7393 475 6182 8187 42 7664 172 7355 8014
Average Medicare benefits 84 5333 548 4101 6244 42 5016 189 4744 5421
Average out-of- pockets 84 2059 188 1671 2551 42 2648 82 2525 2909
Frozen Cycles Obs Mean SD Min Max Obs Mean SD Min Max
No of Patients 84 594 147 337 1074 35 654 140 428 1040
Number of Services 84 696 178 383 1248 35 772 171 496 1255
Average Fees 84 2097 106 1827 2373 42 2367 89 2208 2731
Average Benefits 84 1447 153 1121 1756 42 1323 71 1210 1427
Average OOP 84 650 94 483 858 42 1044 95 935 1317
IUI Cycles Obs Mean SD Min Max Obs Mean SD Min Max
No of Patients 84 264 155 84 674 35 265 136 119 641
Number of Services 84 394 229 127 1015 35 370 193 158 923
Average Fees 84 1381 159 1102 1786 42 1195 66 1064 1386
Average Benefits 84 1007 151 731 1372 42 542 21 505 580
Average OOP 84 374 59 292 547 42 653 62 546 849
All dollar figures in constant 2010 Australian dollars. Cycle costs do not include pharmaceuticals and hormones. OOP denotes patient out-of-pocket expenses.
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Fresh Cycles it is important to investigate if the EMSNCap
policy decreased not only the number of Fresh Cycles, but











Note: Black lines represent service counts adjusted for anticipatory behaviour.
Figure 2 Number of treatment cycles, all ages Australia 2007-2011. So
Service Branch.using Equation (1) were used for this purpose and
reported in Table 5. Overall the number of women
accessing Fresh Cycles decreased by 233 patients per
quarter (6524 women over 12 months). The age specific009Q1 Y2009Q2 Y2009Q3 Y2009Q4 Y2010Q1 Y2010Q2 Y2010Q3 Y2010Q4 Y2011Q1
Extended Medicare 
Safety Net Cap 
(EMSNCap) policy 
urce: Medicare service data provided by the Medicare Information
Table 3 Determinants of number of Fresh Cycles undertaken
Base model and lag With anticipatory behaviour and lag
all age all age
Variable Age≤ 33 34≤Age≥39 Age≥40 groups Age≤ 33 34≤Age≥39 Age≥40 groups
EMSNCap effect -305.83* -429.52*** -497.31*** -307.04*** -183.17* -275.63*** -436.91*** -195.24***
143.84 59.82 56.09 72.58 80.23 40.70 63.83 48.20
Lag of D. Variable 0.88*** 0.32** -0.07 0.70*** 0.95*** 0.56*** 0.001 0.82***
0.13 0.10 0.10 0.11 0.06 0.07 0.12 0.06
Season 1 (base)
Season 2 335.00** 132.34** -21.77 123.40** 230.57*** 81.25** -45.02 48.77
94.08 38.29 34.23 45.64 54.22 28.25 36.58 35.29
Season 3 345.06** 158.65*** -76.69* 117.40* 279.29*** 112.51*** -95.47** 66.87
96.6512 34.5121 31.1946 47.48 62.4833 25.8843 33.7326 38.5072
Season 4 62.98 -18.28 -236.29*** -79.41 -42.13 -108.45*** -262.41*** -159.02***
90.82 38.17 33.58 42.29 47.57 27.11 35.10 31.69
Time Trend 26.38* 35.28*** 51.50*** 25.45*** 14.03 20.94** 45.57*** 14.29**
11.98 4.10 5.70 6.30 7.77 3.61 6.59 4.32
Constant -178.31*** 576.37*** 963.39*** 183.49 -122.03 416.99*** 934.94*** 168.30*
126.19 107.59 95.43 110.00 103.93 71.97 100.54 75.76
N 32 48 32 112 32 48 32 112
df 6 6 6 6 6 6 6 6
R squared 0.85 0.81 0.89 0.71 0.94 0.88 0.89 0.81























Table 4 Semi-elasticity of number of services and number of patients after the introduction of EMSNCap Policy (for
Fresh, Frozen and IUI Cycles)
Base model and lag With anticipatory behaviour and lag
all age all age
Variable Age≤ 33 34≤Age≥39 Age≥40 groups Age≤33 34≤Age≥39 Age≥ 40 groups
Fresh Cycles
Number of services -0.22* -0.34*** -0.44*** -0.25*** -0.14* -0.21*** -0.38*** -0.16***
Number of patients -0.19* -0.28*** -0.32*** -0.20*** -0.12* -0.16*** -0.28*** -0.13***
Frozen Cycles
Number of services -0.11* -0.07* -0.09 -0.09** -0.06 -0.08 0.07 -0.04
Number of patients -0.11* -0.07* -0.10 -0.09** -0.07 -0.09* 0.06 -0.05
IUI Cycles
Number of services -0.14** -0.07 0.13 -0.01 -0.04 -0.06 0.12 0.00
Number of patients -0.04 -0.04 0.15 0.02 -0.03 -0.04 0.16* 0.02
OLS Regression method is used for the semi-elasticity models. Estimated coefficients are presented. * Significance at 10%, ** Significance at 5%, *** Significance at
1%. Each column reports a separate model specification.
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est impact of the policy was in older age groups, while
younger women engaged in more anticipatory behaviour.
The semi-log of Equation (1) for number of patients
shows that after accounting for anticipatory behaviour
there was a decrease in the number of patients undergoing
Fresh ART Cycles of 13% for all ages, 12% for womenTable 5 Determinants of the number of patients undergoing
Base model and lag
all
Variable Age≤33 34≤Age≥ 39 Age≥40 gro
EMSNCap effect -259.55 -342.52*** -330.17*** -23
126.39 51.06 44.67 62.
Lag of D. Variable 0.90*** 0.33** -0.10 0.7
0.12 0.11 0.14 0.1
Season 1 (base)
Season 2 310.06** 113.54** -34.50 104
85.99 33.07 29.51 40.
Season 3 325.46** 127.08*** -98.78** 90.
88.17 31.28 28.66 43.
Season 4 67.44 -14.72 -212.63*** -68
81.04 35.35 31.35 37.
Time Trend 23.26* 30.18*** 42.17*** 20.
10.66 4.53 5.69 5.6
Constant -185.66*** 561.15*** 917.83*** 123
112.46 105.92 100.94 98.
N 32 48 32 112
df 6 6 6 6
R squared 0.87 0.78 0.88 0.7
OLS Regression method is used. Estimated coefficients and standard errors are pres
** Significance at 5%, *** Significance at 1%. Each column reports a separate modeaged ≤34 years, 16% for woman aged 34-39 years and 28%
for women aged ≥40 years (Table 4).
Distribution of the number of cycles undertaken in a year
In terms of the number of cycles undertaken by individ-
ual women in a calendar year, all age groups undertook
statistically significantly fewer Fresh Cycles after theFresh Cycles
With anticipatory behaviour and lag
age all age
ups Age≤ 33 34≤Age≥ 39 Age≥40 groups
2.62*** -155.83* -201.41*** -291.93*** -141.46**
61 74.49 33.61 52.81 42.22
7*** 0.96*** 0.60*** -0.04 0.86***
0 0.06 0.08 0.16 0.06
.95* 216.99*** 62.26* -51.00 34.32
93 47.91 25.00 36.27 31.38
78* 267.69*** 80.25** -112.13** 44.48
82 59.22 23.80 33.19 35.47
.20 -23.64 -102.07*** -230.53*** -138.63***
99 44.52 25.59 33.83 28.61
51*** 12.70 16.29*** 38.20*** 11.13**
7 7.32 3.29 6.76 4.01
.85 -130.18*** 378.40*** 896.18*** 127.05***
47 93.02 71.92 110.12 69.31
32 48 32 112
6 6 6 6
3 0.94 0.85 0.87 0.82






















1% 1% 3% 2% 8% 4% 3% 2%
2007-09 2010 2007-09 2010 2007-09 2010 2007-09 2010
1 cycle 2 cycles 3 cycles ≥ 4 cycles
≤ 34 years 34- 39 years ≥ 40 years All ages
Figure 3 Percentage of patients undertaking 1 or more Fresh Cycles per year before and after the EMSNCap policy.
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http://www.biomedcentral.com/1472-6963/12/142EMSNCap policy (p< 0.05). For example, of women
aged ≥40 year olds, 49% had more than 1 cycle a year
before the policy, but this decreased to 33% of ≥40 yearTable 6 Determinants of number of Frozen Cycles undertaken
Base model and lag
all
Variable Age≤33 34≤Age≥39 Age≥ 40 gro
EMSNCap effect -90.14 -50.24* -35.17 -59
45.76 20.56 25.85 24.
Lag of D. Variable 0.97*** 0.62*** 0.54* 0.9
0.07 0.13 0.21 0.0
Season 1 (base)
Season 2 79.41* -81.01** -108.96*** -69
37.06 28.25 28.95 21.
Season 3 142.93** -48.96* -114.18*** -30
48.55 23.59 22.17 23.
Season 4 -13.55 -133.59*** -175.47*** -12
37.56 25.04 22.98 21.
Time Trend 7.94 7.03*** 10.11*** 6.0
4.18 3.09 2.58 2.4
Constant -68.45*** 308.07*** 273.69** 83.
65.82 71.06 78.96 34.
N 32 48 32 112
df 6 6 6 6
R squared 0.92 0.71 0.87 0.8
OLS Regression method is used. Estimated coefficients and standard errors are pres
** Significance at 5%, *** Significance at 1%. Each column reports a separate modeold women after the policy. This trend was seen in all
age groups but was more pronounced in the older age
groups (Figure 3). This indicates that of women who canWith anticipatory behaviour and lag
age all age
ups Age≤33 34≤Age≥39 Age≥ 40 groups
.55* -38.81 -58.57* 55.71 -26.62
07 45.34 22.29 28.44 26.25
2*** 0.97*** 0.59*** 0.18 0.92***
6 0.06 0.13 0.18 0.05
.09** 24.84 -72.15* -99.61** -102.30***
47 41.84 28.55 33.33 23.52
.31 110.68* -43.48 -105.86** -50.03*
94 49.01 23.81 28.91 24.67
7.38*** -58.60 -125.68*** -193.05*** -155.11***
83 37.75 25.33 27.67 22.09
5* 2.90 8.07* 6.77* 2.92
5 3.79 3.16 2.34 2.38
05* -4.29 320.05*** 466.51*** 127.48***
55 59.81 72.13 69.14 37.82
32 48 32 112
6 6 6 6
7 0.92 0.69 0.88 0.85
ented. df denotes the degrees of freedom. * Significance at 10%,
l specification.
Table 7 Determinants of the number of patients undergoing Frozen Cycles
Base model and lag With anticipatory behaviour and lag
all age all age
Variable Age≤33 34≤Age≥39 Age≥40 groups Age≤ 33 34≤Age≥ 39 Age≥40 groups
EMSNCap effect -73.96 -46.79* -36.78 -53.04* -41.59 -56.59*** 41.87 -27.31
40.07 17.34 22.78 20.93 36.48 19.98 24.30 23.57
Lag of D. Variable 0.97*** 0.63*** 0.51* 0.91*** 0.97*** 0.58*** 0.24 0.90***
0.07 0.11 0.20 0.06 0.06 0.13 0.17 0.06
Season 1 (base)
Season 2 79.51* -58.75** -86.95** -47.08* 45.19 -48.91* -95.54** -72.65***
29.84 21.50 25.75 18.15 32.44 22.89 29.12 20.39
Season 3 131.32** -34.06 -89.68*** -15.67 111.08** -28.14 -94.70*** -30.90
39.86 18.09 19.54 20.04 38.79 18.89 25.15 21.07
Season 4 33.76 -92.77*** -139.64*** -81.78*** 5.10 -84.06*** -166.53*** -103.17***
31.91 19.69 20.56 18.83 29.80 20.61 24.60 19.33
Time Trend 6.72 5.96* 9.12*** 5.33* 3.50 7.22 5.12* 2.94
3.62 2.47 2.22 2.11 3.09 2.66 2.06 2.08
Constant -73.39*** 249.38*** 236.99*** 61.64*** -35.46*** 268.82*** 387.39*** 99.02**
55.99 57.48 66.35 31.99 49.41 62.74 59.05 35.34
N 32 48 32 112 32 48 32 112
df 6 6 6 6 6 6 6 6
R squared 0.92 0.71 0.84 0.85 0.92 0.67 0.86 0.83
OLS Regression method is used. Estimated coefficients and standard errors are presented. df denotes the degrees of freedom. * Significance at 10%,
** Significance at 5%, *** Significance at 1%. Each column reports a separate model specification.
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http://www.biomedcentral.com/1472-6963/12/142afford to have at least one Fresh Cycle, they may not be
able to afford the number of cycles they desire in a year.
The clinical implication of this is that women may be
delaying desired treatment, making them older and less62% 63% 63% 63%
25% 24% 24% 23%
9% 9% 9% 9%
5% 4% 4% 5%
2007-09 2010 2007-09 2010
1 cycle 2 cycles
≤ 34 years 34- 39 years
Figure 4 Percentage of patients undertaking 1 or more Frozen Cycleslikely to achieve a pregnancy, for example between 34
and 39 years each additional year of age decreases a
women’s chance of a live birth following a Fresh Cycle
by 9.6% [12].65% 64% 63% 63%
22% 23% 24% 24%
9% 8% 9% 9%
4% 5% 4% 5%
2007-09 2010 2007-09 2010
3 cycles ≥ 4 cycles
≥ 40 years All ages
per year before and after the EMSNCap policy.
Table 8 Determinants of number of IUI Cycles undertaken
Base model and lag With anticipatory behaviour and lag
all age all age
Variable Age≤33 34≤Age≥39 Age≥40 groups Age≤33 34≤Age≥39 Age≥ 40 groups
EMSNCap effect -79.21** -22.85 21.25* -59.55 3.36 -9.30 18.14 -1.43
27.87 13.25 10.88 24.07 38.94 16.75 15.93 15.81
Lag of D. Variable -480.27*** 256.94 64.32 0.92 0.99*** 0.84*** 0.14 0.97***
16.30 22.18 23.48 0.06 0.04 0.07 0.20 0.03
Season 1 (base)
Season 2 122.57*** -22.27 -8.17 45.30 73.13* -35.75* -5.55 -13.48
24.83 13.27 8.69 59.14 33.54 13.54 14.71 13.22
Season 3 172.65*** -39.82 -26.86 45.98 14.63 -49.11*** -24.10 -42.19***
24.91 13.04 8.86 63.19 29.16 13.30 14.96 11.54
Season 4 61.92** -110.04** -63.94*** -28.21 -120.60*** -121.66*** -61.02*** -117.94***
20.97 12.92 8.08 56.94 29.85 14.76 12.17 11.89
Time Trend -4.42 1.16 1.20 -0.83 -0.80 -0.27 1.43 -0.23
2.82 1.70 1.23 8.28 3.90 1.85 1.59 1.62
Constant 993.48*** 107.76*** 155.42*** 436.08*** 15.93 114.26** 157.46*** 54.97**
33.95 34.26 12.46 94.98 48.47 36.48 27.73 18.33
N 32 48 32 112 32 48 32 112
df 6 6 6 6 6 6 6 6
R squared 0.98 0.84 0.82 0.85 0.95 0.83 0.70 0.96
OLS Regression method is used. Estimated coefficients and standard errors are presented. df denotes the degrees of freedom. * Significance at 10%,
** Significance at 5%, *** Significance at 1%. Each column reports separate model specification.
Chambers et al. BMC Health Services Research 2012, 12:142 Page 11 of 15
http://www.biomedcentral.com/1472-6963/12/142Access to frozen cycles by age
The econometric estimates of the effect of the EMSNCap
policy on Frozen Cycles are summarised in Tables 6 and
7. In contrast to Fresh Cycles, the coefficient for the
EMSNCaps policy was only statistically significant at the
10% level across all ages (-60 cycles quarter, 1700 cycles
over 12 months) and for women age 34-39 years (-50
cycles per quarter). In percentage terms this represented
an average decrease of 9% in Frozen Cycles due to the
introduction of the EMSNCaps. After accounting for an-
ticipatory behaviour, statistical significance only remained
for women aged 34-39 years (Table 4). The distribution of
the number of Frozen Cycles undertaken by women in a
calendar year was not significantly different before or after
the EMSNCaps (Figure 4).
The contrasting findings of the impact of the EMSN-
Cap policy on Fresh and Frozen Cycles is likely because
Frozen Cycles are cheaper that Fresh Cycles, with aver-
age out-of-pocket expenses for a Fresh Cycle around
$2600 compared to $1000 for a Frozen Cycle (Table 2).
In addition, women who undertook Fresh Cycles prior
to January 2010 - either in anticipation of the EMSN-
Caps or as planned treatment - would be likely to use up
their frozen embryos in 2010 prior to discontinuing
ART treatment or undertaking another Fresh Cycle.
Therefore the impact of the policy with regard to Frozen
Cycles may not become fully evident for some time.Access to IUI cycles by age
Equation (1) was also used to estimate the effect of the
EMSNCap policy on access to IUI Cycles. The estimates
show that the EMSNCap policy had little impact on
overall access to IUI treatment across all age groups.
However, the number of IUI Cycles decreased signifi-
cantly by 79 IUI Cycles per quarter (2200 cycles in
12 months) for women aged ≤34 years, representing a
14% reduction in cycles due to the EMSNCaps in this
age group. This effect were eliminated after adjusting for
anticipatory behaviour (Tables 4, 8 and 9). IUI is a
less invasive and cheaper alternative to ART, with
estimated out-of-pocket expenses of $650, which may
explain why it was unaffected by the EMSNCaps. IUI
is often used as a first-line treatment option for infer-
tility before patient’s progress to ART, or as an alter-
native (substitute) to ART treatment. However, it has
the disadvantages of lower success rates (approxi-
mately 10-15% per cycle, compared to 20-30% for
ART) and less controllable means of minimising the
risk of multiple births.
Medicare benefits savings and number of cycles not
performed due to policy
Table 10 summarises the savings in Medicare benefits to
the Australian Government as a result of the EMSNCap
policy. Using the econometric models to estimate the
Table 9 Determinants of number of patients undergoing IUI Cycles
Base model and lag With anticipatory behaviour and lag
all age all age
Variable Age≤33 34≤Age≥39 Age≥40 groups Age≤ 33 34≤Age≥39 Age≥40 groups
EMSNCap effect -14.44 -8.04 19.87*** -5.30 2.16 -4.36 17.49 0.37
24.76 8.24 7.10 9.20 25.65 8.99 9.13 9.39
Lag of D. Variable 0.99*** 0.90*** 0.25 0.98*** 0.99*** 0.89*** 0.27 0.97***
0.04 0.06 0.13 0.03 0.04 0.06 0.19 0.023
Season 1 (base)
Season 2 57.51** -19.46* -8.81 -3.79 44.76 -23.11*** -8.61 -8.46
19.11 7.28 8.48 7.96 21.82 7.64 8.56 8.07
Season 3 22.82 -30.52*** -20.25* -21.89** 14.83 -32.58*** -20.43** -24.77**
19.56 7.17 8.01 7.48 20.40 7.61 8.62 7.50
Season 4 -49.43** -71.08*** -40.98*** -63.29*** -61.90** -74.04*** -40.29*** -67.68***
17.29 7.54 6.45 7.05 18.38 7.82 7.13 7.13
Time Trend 0.90 0.45 0.88 0.38 -0.61 0.09 1.01 -0.14
2.40 0.10 0.83 0.93 2.38 0.96 0.89 0.95
Constant -10.06 52.81** 95.94*** 25.99* 7.82 58.33** 92.27*** 32.29**
27.85 17.29 9.93 10.17 29.77 17.61 16.82 10.53
N 32 48 32 112 32 48 32 112
df 6 6 6 6 6 6 6 6
R squared 0.96 0.89 0.85 0.97 0.96 0.88 0.81 0.97
OLS Regression method is used. Estimated coefficients and standard errors are presented. df denotes the degrees of freedom. * Significance at 10%,
** Significance at 5%, *** Significance at 1%. Each column reports separate model specification.
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fits paid, it was estimated the $84.2 million was saved in
the first year after the EMSNCaps ($76.2 million after
adjusting for anticipatory behaviour). Further, almost
6900 ART cycles were not undertaken in 2010 (5426
after adjusting for anticipatory behaviour) as a result of
the EMSNCap policy, equating to approximately 1540
ART babies not being born in 2010 (1209 after adjusting
for anticipatory behaviour).
Discussion
This paper used econometric models to evaluate the
introduction of a policy change in January 2010 which
capped the amount the Australian Government pays in
benefits for ART and IUI treatment cycles. In effect this
policy removed the government’s exposure to increases
in provider fees and strengthened price signals to
patients. Because fees remained relatively stable after the
introduction of the EMSNCaps, the out-of-pocket costs
to patients for ART and IUI treatment increased on aver-
age by $500-$1000 for Fresh Cycles, and $300-$500 for
Frozen Cycles and IUI Cycles. For Fresh Cycles, this
resulted in a significant reduction in cycles across all age
groups. After accounting for anticipatory behaviour -
where women brought forward their treatment to 2009
to avoid the price rise - the policy reduced the number ofFresh Cycles in the 15 months after the policy by 16%.
The impact of the policy was particularly evident in the
older age groups; with an average reduction of 14% for
women aged ≤34 years (10% significance), 21% reduction
for woman aged 34-39 years (1% significance) and 38%
reduction for women aged ≥40 years (1% significance). In
contrast the policy did not have a significant impact on
utilisation of Frozen Cycles after adjusting for anticipa-
tory behaviour, nor did it have a significant impact of IUI
cycles. These results were reflected in the distribution of
women having one, two, three or four or more cycles per
year during the pre and post EMSNCap periods. There-
fore, not only did fewer women access Fresh Cycles after
the policy change, but those who did underwent fewer
Fresh Cycles in 2010. Further research is needed to eluci-
date why the policy differentially affected access to treat-
ment by older women who conceivable could have more
economic resources to fund fertility treatment than
younger women.
While the data indicated that Frozen Cycles, which are
substantially cheaper than Fresh Cycles, were not affected
by the policy, this may be a temporary phenomenon. A
Frozen Cycle can only proceed a Fresh Cycle that created
the embryos to be transferred, therefore it is likely that
women used up their stored Frozen embryos in 2010 and
may not return for subsequent Fresh Cycles. This is
Table 10 Savings in Medicare benefits, and the number of ART children not born in 2010 as a result of the EMSNCap policy




Fresh Cycles per cycle Cycles savings Cycles savings
Predicted benefits and reduction in cycles - without policy: $6199 5451 $33,790,749 4017 $24,901,383
Observed benefits and number of cycles - with policy: $5108 31,504 $32,341
Savings due to policy ($1091) 31,504 $34,366,787 32,341 $35,279,845
Total savings Fresh Cycles $68,157,536 $60,181,228
Live-birth rate per Fresh Cycle 21% 21%
ART live-births not born due to policy 1145 844
ART Multiple-birth rate 10.2% 10.2%
ART infants not born due to policy 1261 930
Frozen Cycles *
Predicted Avr benefits and reduction in cycles without policy: $1638 1409 $2,307,942 1,409 $2,307,942
Actual benefits and number of cycles with policy: $1348 21,276 21,276
Savings due to policy ($290) 21,276 $6,171,063 21,276 $6,171,065
Total savings Frozen Cycles $8,479,005 $8,479,005
Live-birth rate per Frozen Cycle 18% 18%
ART live-births not born due to policy 254 254
Multiple-birth rate 10.2% 10.2%
ART infants not born due to policy 279 279
IUI Cycles * +
Predicted Avr benefits and reduction in cycles without policy: $1270
Observed benefits and number of cycles with policy: $549 10,504 10,504
Savings due to policy ($721) 10,504 $7,571,632 10,504 $7,571,632
Total savings IUI Cycles $7,571,632 $7,571,632
Total Savings in Medicare benefits $84,208,172 $76,231,865
Total ART infants not born due to policy 1540 1209
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observed for Fresh Cycles in late 2009.
A limitation of this study was that the evaluation was
restricted to 15 months after the introduction of the pol-
icy change. It remains to be seen if the utilisation rates
and growth return to pre policy levels. An analysis of the
introduction of co-payments from ‘no-fees’ to €1500-
2000 for Fresh Cycles in Germany in 2004 found a 53%
reduction in cycles in the first year after the policy [13].
Analysis of more recent German registry data indicates
that utilisation for Fresh Cycles remains at 50% of 2003
levels in 2006 [3]. The German policy analysis also found
that demand for ovulation induction therapy remained
independent of the demand for ART treatments which is
consistent with our findings with respect to demand for
IUI. For some women ARTs are their only chance for
achieving a pregnancy, and most women will undertake
less invasive and expensive treatments, such as ovulation
induction and IUI, before resorting to ART.
The estimated savings to the government in the first
year after the policy was introduced was $84.2 million
($76.2 after adjusting for anticipatory behaviour), more
than the $69.4 million estimated on behalf of the gov-
ernment [10]. These savings accounted for only 0.47% of
Medicare benefits paid in 2009 [14]. While the savings
in Medicare benefits estimated in this policy evaluation
are not dissimilar to those projected on behalf of the
Australian Government, the later analysis did not inves-
tigate the age-specific impact of the policy, use econo-
metric methods to look at the impact of the policy on
uptake of different cycle types, and did not estimate the
number of ART children not born as a consequence of
the policy.
In terms of access to treatment, conservatively 16% of
women who were able to afford ART treatment in 2009,
could not afford to undertake the treatment in 2010.
This translated into between 1200 and 1500 ART babies
not being born in 2010 in Australia. When these results
were announced in November 2011, it caused consider-
able media coverage and debate [15,16]. Evaluating ART
treatment using purely traditional health economic
methods, such at cost-effectiveness and cost-utility ana-
lyses, is problematic because ARTs, unlike other health-
care interventions, are judged by their ability to create
life rather than to extend or improve quality of life. This
creates challenges for health economists and policy
makers when making decisions about healthcare resour-
cing. An alternate method of valuing the worth of ART
treatment in economic terms is to consider ART treat-
ment as an investment from a government accounts per-
spective. One study that took this approach found that
ART treatment represents an 8-fold return on invest-
ment based on the net future tax revenues of ART con-
ceived children [17]. Due to these methodologicalchallenges and strong sociocultural norms associated
with ARTs, they are often targeted for funding cuts or
increases as evidenced by the frequent changes in fund-
ing in Australia and throughout Europe [8].
It should be recognised that it is not only the infertile
couple that suffers when funding is reduced but the
quality of ART clinical practice, which ultimately nega-
tively impacts the health outcomes of ART children. A
number of studies in the United States [18-22] and Aus-
tralia [23], have shown that when ART treatment costs
increase, not only is equity of access reduced, but a fi-
nancial incentive is created to transfer multiple embryos
during treatment, thereby increasing the chance of a
pregnancy in one cycle (i.e. it is costly to fail treatment
and pay for another cycle). For example, in countries
with supportive funding for ART such as the Nordic
Countries and Australia the percentage of cycles where
one embryo is transferred during treatment (single
embryo transfer), is over 65%. This is in stark contrast to
15% of cycles in the UK which has very limited public
funding for ART, and less than 12% of cycles in the Uni-
ted States which has no public funding for ART [3,5].
Therefore, less affordable treatment can lead to
increased rates of twins and triplets, who have signifi-
cantly higher risks of preterm birth, low birth rates,
cerebral palsy and long term health problems [24-26]. A
recent study from Australia showed that the positive
trend to single embryo transfer from 29.5% of cycles in
2002 to 67.7% of cycles in 2008 resulted in the reduction
in the multiple birth rates from 18.8% to 8.6% of ART
births over the same period. The savings in birth-
admission costs alone to the Australian Government
was $48 million, theoretically funding over 50% of the
increase in ART utilisation since 2002 and the birth of
2800 ART babies [23].
Conclusions
This policy evaluation of recent changes to public fund-
ing for ART in Australia found that access to Fresh
Cycles was significantly reduced for all age groups. With
demand for ART treatment likely to increase due to the
trend later childbearing, growing rates of obesity and
some sexually transmitted diseases [27], it is important
that changes to ART funding consider not only equitable
access to treatment but its impact on clinical practice
and the welfare of ART children and their families.
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